Not all of the statistics are disclosed here however it would seem that cx bladder has found an important niches in the clinic.
Those looking for a magic bullet to completely replaces cystoscopy may be disappointed. Those looking for an adjunct test that reduces the required frequency and cost of cystoscopy examinations (e.g. patients and hospital accountants and those clinicians that don't use unnecessary cystoscopy to stay rich) will be very happy IMHO.
The other niche clinical applicaton is to identify the possibility of upper urinary tract cancers that may be missed by cystoscopy .
All will be revealed to the global urologist community soon as we await KP's commercial decision.
cheers
- Forums
- ASX - By Stock
- AN1
- PEB: Positive Results in Kaiser Permanente User Programme
PEB: Positive Results in Kaiser Permanente User Programme, page-17
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online